|
HS Code |
772584 |
| generic_name | Hexoprenaline |
| drug_class | Beta-2 adrenergic agonist |
| molecular_formula | C18H23N3O3 |
| indications | Asthma, preterm labor (tocolytic agent) |
| route_of_administration | Oral, intravenous, inhalation |
| mechanism_of_action | Stimulates beta-2 adrenergic receptors leading to bronchodilation and uterine relaxation |
| half_life | Approximately 50-70 minutes |
| dosage_form | Tablet, injection, syrup, inhaler |
| common_side_effects | Tremor, tachycardia, headache, palpitations |
| contraindications | Hypersensitivity, severe hypertension, thyrotoxicosis |
| ATC_code | R03CC10 |
| brand_names | Gynipral, Iprabron |
As an accredited Hexoprenaline factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Hexoprenaline is packaged in a white carton containing 5 ampoules, each with 2 ml solution (10 mcg/ml), clearly labeled for injection. |
| Shipping | Hexoprenaline is shipped as a regulated pharmaceutical compound. It should be packed in tightly sealed containers to prevent contamination and labeled according to hazardous material guidelines. The shipment typically requires temperature control, protection from light, and secure handling, adhering to relevant local and international shipping and safety regulations for pharmaceuticals. |
| Storage | Hexoprenaline should be stored in a tightly closed container at a temperature below 30°C (86°F), protected from light and moisture. It must be kept out of reach of children and away from incompatible substances. Avoid freezing. Store in accordance with local regulations and manufacturer’s instructions to maintain stability and effectiveness of the product. |
Applications of Hexoprenaline in Industrial ManufacturingHexoprenaline, a selective beta2-adrenergic agonist, plays an important role in pharmaceutical manufacturing with highly regulated downstream applications. As an active pharmaceutical ingredient (API), its utilization remains strictly limited to a handful of high-value, controlled sectors, each governed by rigorous standards. The following scenarios detail its genuine industrial application within regulated environments, focusing on the integration, compliance, composition ranges, and final product categories. 1. Bronchodilator Formulations for Respiratory PharmaceuticalsMedical manufacturers incorporate this compound into bronchodilator medicines designed for conditions such as asthma and chronic obstructive pulmonary disease (COPD). Production batches require adherence to internationally recognized pharmacopeias and documentation for injectable or oral dosage forms. The inclusion level depends on formulation-specific parameters such as dosage strength, delivery route, and pharmacokinetic targets. This raw material integrates at the initial API combination stage, following strict handling and in-process controls. The final bronchodilator products include oral tablets, inhalation solutions, and parenteral injections marketed by downstream pharmaceutical firms under prescription-only status. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
2. Tocolytic Agents in Obstetric Medication ManufacturingDownstream production of tocolytic medicines leverages hexoprenaline as an active ingredient for managing premature labor in specialized obstetric care. Strict maternal health protocols dictate batch formulation, and manufacturers must ensure traceable use of pharmaceutical-grade material with verified purity. The ingredient enters the sterile processing stream at the point of API solution preparation, with critical quality attribute checks for each batch. The finished forms are predominantly parenteral drugs supplied to maternity wards and hospitals under regulatory supervision. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
3. Active Pharmaceutical Ingredient (API) Bulk Supplies for Contract Manufacturing Organizations (CMOs)Bulk hexoprenaline APIs are supplied by manufacturers under controlled conditions to authorized CMOs specializing in finished dose production. Technical agreements stipulate traceability, analytical profile, and certification aligned with target market regulations. Downstream contract processors incorporate the API during scale-up blending or sterile compounding, where process validation and analytical release testing remain mandatory. CMOs typically convert the raw ingredient into semi-finished intermediates or market-ready drugs for hospital procurement channels. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
4. Reference Standards in Analytical Laboratory Reagent ManufacturingAnalytical reagent manufacturers use certified hexoprenaline reference standards to calibrate, qualify, and validate analytical instruments and procedures in quality control laboratories within the pharmaceutical sector. These reference preparations must comply with metrological and traceability requirements, and are produced in dedicated small-batch lots. The material enters the compounding blend at the calibration preparation stage, then undergoes precise weighing and solution preparation for reference ampoules or volumetric solutions. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
|
Competitive Hexoprenaline prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Hexoprenaline has taken on a significant role in the landscape of active pharmaceutical ingredients. Over decades of handling and producing beta-agonists, our team has learned there are few substances that demand both technical skill and practical experience quite like this one. Its molecular structure offers a predictable pathway to stimulating adrenergic receptors, which makes it a trusted choice for those working with respiratory therapeutics. Clients often inquire about reliability and sourcing, which matters considering the strict tolerances many manufacturers set for pharmaceutical compounds. We know firsthand that even minor inconsistencies in purity or particle profile can throw an entire batch off track. In our plant, every step—from input sourcing to final packaging—favors clarity and traceability.
Our journey with Hexoprenaline started long before many modern process controls came onto the scene. Batch records filled with handwritten notes, teams walking the shop floor to watch color and texture shift: all of these habits have formed the backbone of our current precision. These days, our reactors leverage digital controls, and we lean into high-sensitivity analytical equipment to keep tabs on every detail. Chromatographic analysis confirms purity levels before each lot moves into the next phase. Purity hangs around the higher ninety-ninth percentile for most commercial models—the difference shows up not just in a lab report, but in how easy it is for our partners to validate incoming goods. Each lot runs through particle sizing to confirm consistency tailored for both direct formulation and secondary compounding.
Our standard Hexoprenaline presentation comes as a white to off-white crystalline powder. Over the years we've found that proper control of moisture and temperature in storage preserves key functional groups, keeping the compound reliable even after transport. Granule size distribution sticks to a narrow band, the outcome of repeated process tweaks and investing in sieving equipment that can’t be faked with shortcuts. We never fell into the temptation of relaxed dry-room controls; temperature and humidity directly affect moisture pick-up, and those numbers matter at release testing. For anyone tracking CAS numbers or regulatory standards, we meet or exceed most pharmacopoeial guidelines for residual solvents, heavy metals, and microbial load. That’s not just for compliance—it makes secondary processing less stressful for formulators who rely on our material.
Producing active materials like Hexoprenaline on a commercial scale involves more than chemistry on paper. Real-world variables—raw material impurities, equipment cleaning cycles, in-process sampling—shape every outcome. Each operator receives focused training on cleaning validation and contamination control because beta-agonists sit at the intersection of therapeutic value and regulatory scrutiny. We schedule regular downtime for deep cleaning, especially since cross-contamination risk always exists when your plant handles a spectrum of APIs. Quality teams focus as much on batch-to-batch review as on product release because a single anomaly can disrupt dozens of client schedules downstream.
Not all sources produce the same result. Since we keep direct control over every production phase, we identify and remove sources of batch variability at their origin. This matters for pharmaceutical customers who calibrate machinery based on predictability—not just potency numbers on a certificate. We saw early on how storage conditions and trace metals could impact long-term stability. For that reason, we filter not only for purity but also for trace ionic content, using high-grade resins and controlled water purification at each washing step. Shelf life extends well beyond official labels when initial handling respects molecule sensitivity.
Some companies bring Hexoprenaline in through intermediaries, losing visibility on storage and shipping details. We prefer keeping logistics under our umbrella so we guarantee shipment conditions: temperature logging during transit, moisture barrier packaging, and audit trails linking back to primary synthesis. This tight control helps our partners maintain their own records for external audits—no surprises when documentation gets reviewed.
Every chemist remembers their first exposure to the nitty-gritty of active compound handling. It’s easy to overlook small habits: wearing gloves, monitoring dust in the air, protecting against accidental spills. Over the years, we’ve refined workflows in the plant that minimize personnel risk and environmental exposure. Direct handling time stays low, material transfer protocols are built on physical barriers and controlled airflow, and all staff understand the response plan if something goes off-spec. We pay equal attention to what happens after goods leave our door. Packaging reflects this: every drum and container incorporates multiple moisture layers, and labels flag sensitive lots for expedited handling at transfer points.
Few things validate a process like seeing your work integrated into a real finished product. Customers return to our Hexoprenaline because they trust that it won’t undermine their own batch processes. Respiratory medication manufacturers tell us they value knowing each shipment lands with the same appearance, flow profile, and assay results as the previous one. Variability costs time; it sends troubleshooting teams digging for causes, which pulls focus from development. Our API keeps them focused on what matters—end-user safety and product launch timelines.
Some partners operate in geographies where storage space runs tight, and they demand longer shelf stability. We’ve repeatedly revisited our crystallization and drying steps to extend usable life without need for special stabilizing additives. It’s a challenge to provide a stable yet unadulterated product, but, in practice, it cuts costs and decision points for customers managing inventory in unpredictable climates.
Comparisons between Hexoprenaline and other adrenergic agonists often revolve around fines, moisture absorption, and trace impurities. After working through countless rounds of process improvement, we noticed that even slight tweaks in synthesis temperature or pH shift the impurity spectrum. By stabilizing our upstream processes, we avoid some of the recurring stability concerns seen in less rigorous facilities. Some compounds, especially generic-sourced APIs, arrive with slightly higher residual solvent content or unfiltered micron sizes, which show up later in blending or finished product behavior. Our focus stays on clean product lines—single source inputs, validated synthesis path, and no shortcutting drying or sieving.
We avoid overpromising, but our customers find fewer interruptions due to off-specification complaints. Building on long-term partnerships, many clients supply their own feedback—alerting us to trends or equipment interfacing issues, so we can trace root causes on our end. No supply chain is perfect, but a transparent feedback loop closes the gap.
Our QA process stands on reproducibility and long-term trend tracking. Every released lot gets a full panel of purity checks—HPLC, titration, pH analysis, and trace metals quantification. Instead of relying solely on end-point testing, we batch monitor throughout synthesis and drying, catching outliers before packaging ever begins. We maintain reference samples on-site for every batch, supporting later investigation if questions ever arise.
We keep methods up to date with evolving pharmacopoeial standards, adopting stricter cut-offs when updates occur. Routine stability testing simulates real-world storage conditions, tracing actual shelf-life data to back up any claimed figures. There’s no shortcut for real retention studies: our records stretch back years, forming a reliable basis for shelf-life and handling recommendations.
Clients in regulated markets ask where APIs originate, what controls exist during transport, and if documentation lines up with regulatory requirements. Having been asked these questions repeatedly, we've shaped our supply chain around transparency. Full traceability comes with every shipment—synthesized under our roof, tracked through every holding zone. Real decisions rest on documentation and visible audits, not just trust or promises. Auditors inspect our facilities semi-annually, and we hold third-party validation records ready for review. We transitioned early to electronic batch recordkeeping, providing crystal-clear history even years after original production.
Our experience tells us that straightforward answers matter more than marketing polish. If a process goes off-track, we report it and fix it, not just polish data for review. We're open about origins, deviations, and corrective actions—practical details that help our customers manage their own documentation burden.
Running a modern production facility means facing the environmental realities of chemical synthesis. We put a lot of effort into solvent recovery, waste minimization, and air handling. Hexoprenaline synthesis uses intermediates and solvents that present handling risks, especially if uncontrolled. Our in-house reclamation units help lower emissions, while trained crews manage hazardous material cycles with strict oversight. Some see these efforts as regulatory-driven, but in the real world, responsible waste management lowers operational costs and keeps us in good standing with local authorities. We fit production schedules around maintenance and environmental checks, keeping plant operation predictable and continuous.
Each decision creates knock-on effects: choosing higher-quality input sources not only improves output quality but reduces purification stages, which in turn cuts down on process waste and total water use. These small but cumulative savings show up on utility bills, discharge records, and ultimately public perception.
No plant runs smoothly all the time. Equipment breakdowns, supplier shortfalls, quality hiccups: these happen to every real manufacturer. Early on, we faced an incident where off-spec input material created a visible purity shift; production paused, investigation teams huddled, and we worked late to trace the cause. Sometimes, disruptions stem from the smallest oversights—an uncalibrated probe or an incomplete solvent flush. Over the years, these lessons built our process control systems and doubled up our operator training. We don’t fear addressing mistakes head-on, as that honesty forms the bedrock of trust with our customers.
Supply chain issues also arise—global shipping interruptions, port closures, or regulatory holdups. Handling these challenges requires real transparency. We keep clients informed of emerging risks, opening alternate logistics channels early. We’ve shipped by both air and sea, worked around customs slowdowns, held product in controlled stores until clearance arrives. Every plant manager learns to value communication and planning more than over-promising or downplaying setbacks.
Drug development teams face a heavy load: regulatory records, market testing, and product scaling. We see our job as more than just delivering raw material. We keep dialogue open with formulation and analytical scientists from our clients, listening carefully to concerns about reactivity, stability, and solubility in new dosage forms. Several times, close collaboration has led us to three or four rounds of production trial, modifying drying or milling conditions to precisely match a partner’s unique process. Having everything under one roof means we can respond quickly and adapt to new requirements—sometimes with just a single phone call or email.
Some customers scale up new products with batches sourced from suppliers across different continents. This patchwork approach often introduces variability—appearance, granule profile, assay values—that blends unpredictably into pilot batches. By working with our team, partners access a predictable stream of supply, freeing up their development teams to focus on science, not crisis management.
We approach sustainable manufacturing as a practical discipline. Our Hexoprenaline line benefits from solvent recapture systems installed after real-world need arose, not as marketing add-ons. By tracking water and energy use right down to each reactor cycle, we’ve managed to shave running costs off each year, passing savings along to our partners. Most environmental progress grows out of incremental habits, not grand public statements: reviewing material flow records, tweaking batch sizes for efficiency, and training staff on energy-mindful operation. These direct actions have produced a stronger operation, both in reliability and cost control.
Evolving pharmacopoeial standards teach us to remain humble yet decisive. Regulators review manufacturing controls with sharper teeth each passing year. We keep direct lines open to regulatory consultants when guidelines change, revising production controls and revalidating analytical methods without delay. Experience has shown us that it’s less disruptive to stay a step ahead rather than scramble for compliance at the last minute. Our records, batch methods, and environmental data stand ready for review—partners know we won’t slow down their own registration process.
Demand for reliable active pharmaceutical ingredients keeps growing, and the bar for quality, traceability, and partner support rises with every round of regulatory review. We pay attention to therapeutic trends and increased focus on respiratory therapy worldwide. Hexoprenaline, with its well-understood mechanism and formulary value, occupies a space where reliability and rapid delivery matter most. We adapt batch sizes to fit market shifts, ready to move quickly if demand rises or new formats develop.
Our partners often bring us early-stage projects, seeking more than just bulk material. In these cases, we offer detailed technical discussions on solubility, bioavailability, and new delivery vehicles. Our laboratory teams test how subtle process changes influence end-product behavior, feeding practical data back to the client’s own team. These efforts anchor us as more than a supplier—we work alongside, not just in parallel.
Stasis never works in chemical production. We dedicate resources to reviewing reactor design, solvent use, and analytics year over year. Recently, we invested in new particle sizing instruments for tighter detection of outliers, reducing manual re-sieving. Upgrades to temperature controlled rooms give more predictable drying and storage, supporting long-term shelf stability for Hexoprenaline lots destined for hot or humid regions. Continuous operator training remains central, not only for safety but for fostering an environment that catches errors early.
We stay alert for new validation protocols, regularly sending our teams out for workshops and technical seminars. The field evolves, and only dynamic facilities withstand both surprise audits and real-world production crunches.
Decades of hands-on experience shape everything we do with Hexoprenaline. Reliability, transparency, and direct control define our manufacturing philosophy. We’ve chosen this path, not just for regulatory comfort, but because real-world production success depends on it. Customers return to us because our work removes uncertainty, allowing their teams to focus on development and end-user impact. Chemical production stays grounded through practical effort, constant learning, and honest communication. This approach brings the best out of Hexoprenaline—batch after batch, year after year.